Adipokines in inflammation, insulin resistance and cardiovascular disease

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 12, 2011, Pages 888-896

  Li, Zhi Yong ^a   Wang, Pei ^a   Miao, Chao Yu ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adipokines; Cardiovascular disease; Inflammation; Insulin resistance; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ANGIOPOIETIN LIKE PROTEIN 2; CYTOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GLUCOSE; HAPTOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKEMIA INHIBITORY FACTOR; LIPID; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; RESISTIN; RETINOL BINDING PROTEIN; SALICYLIC ACID; SCATTER FACTOR; SERUM AMYLOID A; SERUM AMYLOID A3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DIABETOGENESIS; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; FATTY ACID OXIDATION; HEREDITY; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INFLAMMATORY INFILTRATE; INSULIN RESISTANCE; LEUKOCYTE ACTIVATION; MACROPHAGE; MACROPHAGE MIGRATION; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHAGOCYTOSIS; PROTEIN EXPRESSION; SHORT SURVEY;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MICE; OBESITY; RATS;

EID: 82355170609     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05602.x     Document Type: Short Survey

References (88)

1. Finucane MM, Stevens GA, Cowan MJ et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-67.
2. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 2000; 11: 327-32.
3. Beck E, Scheen AJ. Metabolically obese with normal weight individuals: An intriguing phenotype. Rev. Med. Liege 2009; 64: 16-24.
4. Bluher M. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr. Opin. Lipidol. 2010; 21: 38-43.
5. Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab. 2008; 7: 410-20.
6. Bastard JP, Maachi M, Lagathu C et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006; 17: 4-12.
7. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003; 112: 1821-30.
8. Winer DA, Winer S, Shen L et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 2011; 17: 610-7.
9. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 1978; 240: 1607-10.
10. Kurth T, Gaziano JM, Berger K et al. Body mass index and the risk of stroke in men. Arch. Intern. Med. 2002; 162: 2557-62.
11. Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918.
12. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-80.
13. Leclerc V, Reichhart JM. The immune response of Drosophila melanogaster. Immunol. Rev. 2004; 198: 59-71.
14. Cousin B, Munoz O, Andre M et al. A role for preadipocytes as macrophage-like cells. FASEB J. 1999; 13: 305-12.
15. Chung S, Lapoint K, Martinez K, Kennedy A, Boysen Sandberg M, McIntosh MK. Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes. Endocrinology 2006; 147: 5340-51.
16. Meijer K, de Vries M, Al-Lahham S et al. Human primary adipocytes exhibit immune cell function: Adipocytes prime inflammation independent of macrophages. PLoS One 2011; 6: e17154.
17. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 2007; 117: 175-84.
18. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 2005; 96: 939-49.
19. Nicoletti G, Giugliano G, Pontillo A et al. Effect of a multidisciplinary program of weight reduction on endothelial functions in obese women. J. Endocrinol. Invest. 2003; 26: RC5-8.
20. Wang P, Yang FJ, Du H et al. Involvement of leptin receptor (LepRb)-STAT3 signaling pathway in brain FTO downregulation during energy restriction. Mol. Med. 2011; 17: 523-32.
21. Shah R, Hinkle CC, Ferguson JF et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 2011; 60: 1512-8.
22. Cefalu WT. Fractalkine: A cellular link between adipose tissue inflammation and vascular pathologies. Diabetes 2011; 60: 1380-2.
23. Ouchi N, Higuchi A, Ohashi K et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010; 329: 454-7.
24. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 2004; 68: 975-81.
25. Kahn BB, Flier JS. Obesity and insulin resistance. J. Clin. Invest. 2000; 106: 473-81.
26. Gavrilova O, Marcus-Samuels B, Graham D et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 2000; 105: 271-8.
27. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol. Med. 2008; 14: 741-51.
28. Yang RZ, Lee MJ, Hu H et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 2006; 290: E1253-61.
29. Wada J. Vaspin: A novel serpin with insulin-sensitizing effects. Expert Opin. Investig. Drugs 2008; 17: 327-33.
30. Yan QW, Yang Q, Mody N et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007; 56: 2533-40.
31. Ernst MC, Sinal CJ. Chemerin: At the crossroads of inflammation and obesity. Trends Endocrinol. Metab. 2010; 21: 660-7.
32. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 2006; 116: 1784-92.
33. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-30.
34. Revollo JR, Körner A, Mills KF et al. Nampt/PBEF/Visfatin regulates insulin secretion in [beta] cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007; 6: 363-75.
35. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-14.
36. Saddi-Rosa P, Oliveira CSV, Giuffrida FMA, Reis AF. Visfatin, glucose metabolism and vascular disease: A review of evidence. Diabetol. Metab. Syndr. 2010; 2: 1-6.
37. Nozari A, Dilekoz E, Sukhotinsky I et al. Microemboli may link spreading depression, migraine aura, and patent foramen ovale. Ann. Neurol. 2010; 67: 221-9.
38. Yuan M, Konstantopoulos N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673-7.
39. Tataranni PA, Ortega E. A burning question: Does an adipokine-induced activation of the immune system mediate the effect of overnutrition on Type 2 diabetes? Diabetes 2005; 54: 917-27.
40. Schmidt MI, Duncan BB, Sharrett AR et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study. Lancet 1999; 353: 1649-52.
41. Hirosumi J, Tuncman G, Chang L et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
42. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. 2000; 275: 9047-54.
43. Ye J. Regulation of PPARgamma function by TNF-alpha. Biochem. Biophys. Res. Commun. 2008; 374: 405-8.
44. Furukawa S, Fujita T, Shimabukuro M et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004; 114: 1752-61.
45. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J. Clin. Invest. 2006; 116: 1793-801.
46. Sun Z, Arendt CW, Ellmeier W et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000; 404: 402-7.
47. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 2006; 45: 42-72.
48. Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem. Biophys. Res. Commun. 2006; 346: 739-45.
49. Sabio G, Das M, Mora A et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008; 322: 1539-43.
50. Zhang J, Gao Z, Yin J, Quon MJ, Ye J. S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2. J. Biol. Chem. 2008; 283: 35375-82.
51. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int. J. Obes. 2009; 33: 54-66.
52. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am. J. Physiol. Endocrinol. Metab. 2007; 293: E1118-28.
53. Tabata M, Kadomatsu T, Fukuhara S et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab. 2009; 10: 178-88.
54. Weisberg SP, Hunter D, Huber R et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006; 116: 115-24.
55. Romero-Corral A, Montori VM, Somers VK et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: A systematic review of cohort studies. Lancet 2006; 368: 666-78.
56. Adams KF, Schatzkin A, Harris TB et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71years old. N. Engl. J. Med. 2006; 355: 763-78.
57. Debette S, Beiser A, Hoffmann U et al. Visceral fat is associated with lower brain volume in healthy middle-aged adults. Ann. Neurol. 2010; 68: 136-44.
58. Handel AE, Disanto G, Ramagopalan SV. Visceral obesity and brain volume. Ann. Neurol. 2010; 68: 770-1.
59. Wessel TR, Arant CB, Olson MB et al. Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. JAMA 2004; 292: 1179-87.
60. de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: Meta-regression analysis of prospective studies. Eur. Heart J. 2007; 28: 850-6.
61. Bazzano LA, Gu D, Whelton MR et al. Body mass index and risk of stroke among Chinese men and women. Ann. Neurol. 2010; 67: 11-20.
62. Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: Sixteen years of follow-up in US women. Circulation 2008; 117: 1658-67.
63. Kurth T, Leitzmann MF. Awakening of the sleeping giant: Obesity and stroke in China. Ann. Neurol. 2010; 67: 1-2.
64. Shiue I. Does body mass index increase risk of hemorrhagic stroke? Ann. Neurol. 2010; 68: 115-6.
65. Qureshi AI, Feldmann E, Gomez CR et al. Intracranial atherosclerotic disease: An update. Ann. Neurol. 2009; 66: 730-8.
66. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 2000; 148: 209-14.
67. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
68. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4: 361-8.
69. Wang CH, Li SH, Weisel RD et al. C-Reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783-90.
70. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439-41.
71. Verma S, Li SH, Wang CH et al. Resistin promotes endothelial cell activation: Further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-40.
72. Tan HW, Liu X, Bi XP et al. IL-18 overexpression promotes vascular inflammation and remodeling in a rat model of metabolic syndrome. Atherosclerosis 2010; 208: 350-7.
73. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J. Clin. Invest. 2011; 121: 2094-101.
74. Ye J. Adipose tissue vascularization: Its role in chronic inflammation. Curr. Diab. Rep. 2011; 11: 203-10.
75. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: Role of nicotinamide mononucleotide. Cardiovasc. Res. 2009; 81: 370-80.
76. Wang P, Bai C, Xu QY et al. Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2010; 37: 894-9.
77. Wang P, Du H, Zhang RY et al. Circulating and local visfatin/Nampt/PBEF levels in spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats. J. Physiol. Sci. 2010; 60: 317-24.
78. Wang P, Vanhoutte PM, Miao CY. Visfatin and cardio-cerebro-vascular disease. J. Cardiovasc. Pharmacol. Epub 22 January 2011: doi:.
79. Wang P, Xu TY, Guan YF et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann. Neurol. 2011; 69: 360-74.
80. Romacho T, Azcutia V, Vazquez-Bella M et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009; 52: 2455-63.
81. Rosito GA, Massaro JM, Hoffmann U et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: The Framingham Heart Study. Circulation 2008; 117: 605-13.
82. Miao CY, Li ZY. The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br. J. Pharmacol. 2011; Epub 6 April 2011; doi:.
83. Souza DS, Johansson B, Bojo L et al. Harvesting the saphenous vein with surrounding tissue for CABG provides long-term graft patency comparable to the left internal thoracic artery: Results of a randomized longitudinal trial. J. Thorac. Cardiovasc. Surg. 2006; 132: 373-8.
84. Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Circulation 1995; 91: 1432-43.
85. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J. Clin. Endocrinol. Metab. 2001; 86: 713-8.
86. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 1996; 97: 2601-10.
87. Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Jarvinen H. Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes 1999; 48: 821-7.
88. Zhang RY, Qin Y, Lv XQ et al. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase. Anal. Biochem. 2011; 412: 18-25.